

## Caplyta - (10.5 and 21 mg ; Capsule, Oral)

|                              |                                                                                                                                                                                                                                                                    |                             |                     |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Lumateperone Tosylate                                                                                                                                                                                                                                              | <b>Innovator</b>            | Intra-Cellular      |
| <b>Dosage</b>                | 10.5 and 21 mg ; Capsule, Oral                                                                                                                                                                                                                                     | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | More Than 5                                                                                                                                                                                                                                                        | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                        | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                                                               | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Caplyta - (42 mg ; Capsule, Oral)

|                              |                                                                                                                                                                                                                                                                    |                             |                     |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Lumateperone Tosylate                                                                                                                                                                                                                                              | <b>Innovator</b>            | Intra-Cellular      |
| <b>Dosage</b>                | 42 mg ; Capsule, Oral                                                                                                                                                                                                                                              | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | More Than 5                                                                                                                                                                                                                                                        | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                        | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                                                               | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | CAPLYTA is an atypical antipsychotic indicated for the treatment of: • Schizophrenia in adults. • Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.